Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-61

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 647-654

  Puel, Anne ^a,c   Picard, Capucine ^a,c,d   Lorrot, Mathie ^f   Pons, Charlotte ^f   Chrabieh, Maya ^a,c   Lorenzo, Lazaro ^a,c   Mamani Matsuda, Maria ^b,c   Jouanguy, Emmanuelle ^a,c   Gendrel, Dominique ^f   Casanova, Jean Laurent ^a,b,e  

^a INSERM   (France)

^b Laboratoire du Développement du Système Immunitaire   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Centre D'Étude des Déficits Immunitaires   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f Groupe Hospitalier Cochin Saint Vincent de Paul ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AUTOANTIBODY; C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; TOLL LIKE RECEPTOR AGONIST; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CARCINOMA CELL; CASE REPORT; CELL ACTIVATION; CELL STIMULATION; CELLULITIS; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEVER; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIVER CELL CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; SKIN ABSCESS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ABSCESS; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; LYMPHOCYTE; MICROBIOLOGY; RECURRENT DISEASE; SKIN; TUMOR CELL LINE;

ABSCESS; AUTOANTIBODIES; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CELLULITIS; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; LYMPHOCYTES; MALE; RECURRENCE; SKIN; STAPHYLOCOCCAL INFECTIONS;

EID: 40449106777     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.647     Document Type: Article

References (86)

1. Heyworth, P. G., A. R. Cross, and J. T. Curnutte. 2003. Chronic granulomatous disease. Curr. Opin. Immunol. 15: 578-584.
2. Grimbacher, B., S. M. Holland, and J. M. Puck. 2005. Hyper-IgE syndromes. Immunol. Rev. 203: 244-250.
3. Puel, A., C. Picard, C. L. Ku, A. Smahi, and J. L. Casanova. 2004. Inherited disorders of NF-κB-mediated immunity in man. Curr. Opin. Immunol. 16: 34-41.
4. Ku, C. L., K. Yang, J. Bustamante, A. Puel, H. von Bernuth, O. F. Santos, T. Lawrence, H. H. Chang, H. Al-Mousa, C. Picard, and J. L. Casanova. 2005. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol. Rev. 203: 10-20.
5. Minegishi, Y., M. Saito, S. Tsuchiya, I. Tsuge, H. Takada, T. Hara, N. Kawamura, T. Ariga, S. Pasic, O. Stojkovic, et al. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448: 1058-1062.
6. Holland, S. M., F. R. Deleo, H. Z. Elloumi, A. P. Hsu, G. Uzel, N. Brodsky, A. F. Freeman, A. Demidowich, J. Davis, M. L. Turner, et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357: 1608-1619.
7. Arcone, R., G. Gualandi, and G. Ciliberto. 1988. Identification of sequences responsible for acute-phase induction of human C-reactive protein. Nucleic Acids Res. 16: 3195-3207.
8. Castell, J. V., M. J. Gomez-Lechon, M. David, T. Hirano, T. Kishimoto, and P. C. Heinrich. 1988. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232: 347-350.
9. Castell, J. V., M. J. Gomez-Lechon, M. David, T. Andus, T. Geiger, R. Trullenque, R. Fabra, and P. C. Heinrich. 1989. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242: 237-239.
10. Ganter, U., R. Arcone, C. Toniatti, G. Morrone, and G. Ciliberto. 1989. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8: 3773-3779.
11. Heinrich, P. C., J. V. Castell, and T. Andus. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265: 621-636.
12. Li, S. P., T. Y. Liu, and N. D. Goldman. 1990. cis-acting elements responsible for interleukin-6 inducible C-reactive protein gene expression. J. Biol. Chem. 265: 4136-4142.
13. Majello, B., R. Arcone, C. Toniatti, and G. Ciliberto. 1990. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J. 9: 457-465.
14. Zhang, D., M. Sun, D. Samols, and I. Kushner. 1996. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271: 9503-9509.
15. Agrawal, A., H. Cha-Molstad, D. Samols, and I. Kushner. 2001. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein β (C/EBP β) and Rel p50. J. Immunol. 166: 2378-2384.
16. Voleti, B., and A. Agrawal. 2005. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-κB on the proximal promoter. J. Immunol. 175: 3386-3390.
17. Volanakis, J. E. 2001. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38: 189-197.
18. Finnish-German Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Consortium. 1997. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17: 399-403.
19. Nagamine, K., P. Peterson, H. S. Scott, J. Kudoh, S. Minoshima, M. Heino, K. J. Krohn, M. D. Lalioti, P. E. Mullis, S. E. Antonarakis, et al. 1997. Positional cloning of the APECED gene. Nat. Genet. 17: 393-398.
20. Anderson, M. S., E. S. Venanzi, L. Klein, Z. Chen, S. P. Berzins, S. J. Turley, H. von Boehmer, R. Bronson, A. Dierich, C. Benoist, and D. Mathis. 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science 298: 1395-1401.
21. Meager, A., K. Visvalingam, P. Peterson, K. Moll, A. Murumagi, K. Krohn, P. Eskelin, J. Perheentupa, E. Husebye, Y. Kadota, and N. Willcox. 2006. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3: e289.
22. Casanova, J. L., and L. Abel. 2007. Primary immunodeficiencies: a field in its infancy. Science 317: 617-619.
23. Nishimoto, N., and T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
24. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
25. Van der Poll, T., C. V. Keogh, X. Guirao, W. A. Buurman, M. Kopf, and S. F. Lowry. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176: 439-444.
26. Diao, H., and M. Kohanawa. 2005. Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor α production. Infect. Immun. 73: 3745-3748.
27. Van Enckevort, F. H., C. G. Sweep, P. N. Span, M. G. Netea, A. R. Hermus, and B. J. Kullberg. 2001. Reduced adrenal response and increased mortality after systemic Klebsiella pneumoniae infection in interleukin-6-deficient mice. Eur. Cytokine Network 12: 581-586.
28. Cole, N., S. Bao, F. Stapleton, A. Thakur, A. J. Husband, K. W. Beagley, and M. D. Willcox. 2003. Pseudomonas aeruginosa keratitis in IL-6-deficient mice. Int. Arch. Allergy Immunol. 130: 165-172.
29. Dalrymple, S. A., R. Slattery, D. M. Aud, M. Krishna, L. A. Lucian, and R. Murray. 1996. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 64: 3231-3235.
30. Jones, M. R., L. J. Quinton, B. T. Simms, M. M. Lupa, M. S. Kogan, and J. P. Mizgerd. 2006. Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia. J. Infect. Dis. 193: 360-369.
31. Onogawa, T. 2005. Local delivery of soluble interleukin-6 receptors to improve the outcome of α-toxin producing Staphylococcus aureus infection in mice. Immunobiology 209: 651-660.
32. Minegishi, Y., M. Saito, T. Morio, K. Watanabe, K. Agematsu, S. Tsuchiya, H. Takada, T. Hara, N. Kawamura, T. Ariga, et al. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25: 745-755.
33. Whitehead, A. S., K. Zahedi, M. Rits, R. F. Mortensen, and J. M. Lelias. 1990. Mouse C-reactive protein: generation of cDNA clones, structural analysis, and induction of mRNA during inflammation. Biochem. J. 266: 283-290.
34. Mold, C., S. Nakayama, T. J. Holzer, H. Gewurz, and T. W. Du Clos. 1981. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J. Exp. Med. 154: 1703-1708.
35. Yother, J., J. E. Volanakis, and D. E. Briles. 1982. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J. Immunol. 128: 2374-2376.
36. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1995. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J. Immunol. 155: 2557-2563.
37. Weiser, J. N., N. Pan, K. L. McGowan, D. Musher, A. Martin, and J. Richards. 1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J. Exp. Med. 187: 631-640.
38. Serino, L., and M. Virji. 2002. Genetic and functional analysis of the phosphorylcholine moiety of commensal Neisseria lipopolysaccharide. Mol. Microbiol. 43: 437-448.
39. Richardson, M. D., G. S. Shankland, and C. A. Gray. 1991. Opsonizing activity of C-reactive protein in phagocytosis of Aspergillus fumigatus conidia by human neutrophils. Mycoses 34: 141-143.
40. Richardson, M. D., C. A. Gray, and G. S. Shankland. 1991. Opsonic effect of C-reactive protein on phagocytosis and intracellular killing of virulent and attenuated strains of Candida albicans by human neutrophils. FEMS Microbiol. Immunol. 3: 341-344.
41. Kindmark, C. O. 1971. Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. Clin. Exp. Immunol. 8: 941-948.
42. Mold, C., C. P. Rodgers, R. L. Kaplan, and H. Gewurz. 1982. Binding of human C-reactive protein to bacteria. Infect. Immun. 38: 392-395.
43. Szalai, A. J., J. L. VanCott, J. R. McGhee, J. E. Volanakis, and W. H. Benjamin, Jr. 2000. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect. Immun. 68: 5652-5656.
44. Suresh, M. V., S. K. Singh, D. A. Ferguson, Jr., and A. Agrawal. 2007. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J. Immunol. 178: 1158-1163.
45. Madariaga, L., C. Amurrio, G. Martin, F. Garcia-Cebrian, J. Bicandi, P. Lardelli, M. D. Suarez, and R. Cisterna. 1998. Detection of anti-interferon- γ autoantibodies in subjects infected by Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2: 62-68.
46. Doffinger, R., M. R. Helbert, G. Barcenas-Morales, K. Yang, S. Dupuis, L. Ceron-Gutierrez, C. Espitia-Pinzon, N. Barnes, G. Bothamley, J. L. Casanova, et al. 2004. Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38: e10-e14.
47. Hoflich, C., R. Sabat, S. Rosseau, B. Temmesfeld, H. Slevogt, W. D. Docke, G. Grutz, C. Meisel, E. Halle, U. B. Gobel, et al. 2004. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103: 673-675.
48. Patel, S. Y., L. Ding, M. R. Brown, L. Lantz, T. Gay, S. Cohen, L. A. Martyak, B. Kubak, and S. M. Holland. 2005. Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175: 4769-4776.
49. Kampmann, B., C. Hemingway, A. Stephens, R. Davidson, A. Goodsall, S. Anderson, M. Nicol, E. Scholvinck, D. Relman, S. Waddell, et al. 2005. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J. Clin. Invest. 115: 2480-2488.
50. Bendtzen, K., M. Svenson, V. Jonsson, and E. Hippe. 1990. Autoantibodies to cytokines: friends or foes? Immunol. Today 11: 167-169.
51. 2b and human IFN-γ in healthy blood donors. Clin. Exp. Immunol. 82: 57-62.
52. Svenson, M., M. Bagge Hansen, and K. Bendtzen. 1990. Distribution and characterization of autoantibodies to interleukin 1α in normal human sera. Scand. J. Immunol. 32: 695-701.
53. Hansen, M. B., M. Svenson, and K. Bendtzen. 1991. Human anti-interleukin 1α antibodies. Immunol. Lett. 30: 133-139.
54. Suzuki, H., T. Ayabe, J. Kamimura, and H. Kashiwagi. 1991. Anti-IL-1α autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin. Exp. Immunol. 85: 407-412.
55. 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 85: 80-84.
56. 2a treatment. Clin. Exp. Immunol. 89: 330-335.
57. Svenson, M., M. B. Hansen, L. Kayser, A. K. Rasmussen, C. M. Reimert, and K. Bendtzen. 1992. Effects of human anti-IL-1α autoantibodies on receptor binding and biological activities of IL-1. Cytokine 4: 125-133.
58. Tiberio, L., A. Caruso, A. Pozzi, L. Rivoltini, D. Morelli, E. Monti, and A. Balsari. 1993. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand. J. Immunol. 38: 472-476.
59. Satoh, H., R. Chizzonite, C. Ostrowski, G. Ni-Wu, H. Kim, B. Fayer, N. Mae, R. Nadeau, and D. J. Liberato. 1994. Characterization of anti-IL-1α autoantibodies in the sera from healthy humans. Immunopharmacology 27: 107-118.
60. Hansen, M. B., M. Svenson, K. Abell, K. Varming, H. P. Nielsen, A. Bertelsen, and K. Bendtzen. 1994. Sex- and age-dependency of IgG auto-antibodies against IL-1 α in healthy humans. Eur. J. Clin. Invest. 24: 212-218.
61. Garrone, P., O. Djossou, F. Fossiez, J. Reyes, S. Ait-Yahia, C. Maat, S. Ho, T. Hauser, J. M. Dayer, J. Greffe, et al. 1996. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitor. Mol. Immunol. 33: 649-658.
62. Muller, K., M. B. Hansen, M. Zak, S. Nielsen, F. K. Pedersen, P. de Nully, and K. Bendtzen. 1996. Autoantibodies to IL-1α in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. Scand. J. Rheumatol. 25: 164-167.
63. Jouvenne, P., F. Fossiez, P. Garrone, O. Djossou, J. Banchereau, and P. Miossec. 1996. Increased incidence of neutralizing autoantibodies against interleukin-1 α (IL-1α) in nondestructive chronic polyarthritis. J. Clin. Immunol. 16: 283-290.
64. Menetrier-Caux, C., F. Briere, P. Jouvenne, E. Peyron, F. Peyron, and J. Banchereau. 1996. Identification of human IgG autoantibodies specific for IL-10. Clin. Exp. Immunol. 104: 173-179.
65. Nolte, K. U., G. Gunther, and P. von Wussow. 1996. Epitopes recognized by neutralizing therapy-induced human anti-interferon-α antibodies are localized within the N-terminal functional domain of recombinant interferon-α2. Eur. J. Immunol. 26: 2155-2159.
66. Bonino, F., M. Baldi, F. Negro, F. Oliveri, P. Colombatto, G. Bellati, and M. R. Brunetto. 1997. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-α. J. Interferon Cytokine Res. 17 (Suppl. 1): S35-S38.
67. Ross, C., M. Svenson, H. Nielsen, C. Lundsgaard, M. B. Hansen, and K. Bendtzen. 1997. Increased in vivo antibody activity against interferon α, interleukin-1α, and interleukin-6 after high-dose Ig therapy. Blood 90: 2376-2380.
68. Bendtzen, K., M. B. Hansen, C. Ross, and M. Svenson. 1998. High-avidity autoantibodies to cytokines. Immunol. Today 19: 209-211.
69. Mizutani, H., Y. Ohmoto, T. S. Kupper, and M. Shimizu. 1998. Endogenous neutralizing anti-IL-1α autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1. J. Dermatol. Sci. 20: 63-71.
70. Svenson, M., M. B. Hansen, C. Ross, M. Diamant, K. Rieneck, H. Nielsen, and K. Bendtzen. 1998. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91: 2054-2061.
71. Meager, A., M. Wadhwa, C. Bird, P. Dilger, R. Thorpe, J. Newsom-Davis, and N. Willcox. 1999. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 97: 526-532.
72. Scagnolari, C., F. Bellomi, O. Turriziani, F. Bagnato, V. Tomassini, V. Lavolpe, M. Ruggieri, F. Bruschi, G. Meucci, G. Dicuonzo, and G. Antonelli. 2002. Neutralizing and binding antibodies to IFN-β: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J. Interferon Cytokine Res. 22: 207-213.
73. + T cells. J. Neuroimmunol. 139: 102-108.
74. Shiono, H., Y. L. Wong, I. Matthews, J. L. Liu, W. Zhang, G. Sims, A. Meager, D. Beeson, A. Vincent, and N. Willcox. 2003. Spontaneous production of anti-IFN-α and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15: 903-913.
75. Hansen, M. B., M. Svenson, M. Diamant, and K. Bendtzen. 1991. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33: 777-781.
76. Hansen, M. B., M. Svenson, M. Diamant, and K. Bendtzen. 1993. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5: 72-80.
77. Svenson, M., M. B. Hansen, and K. Bendtzen. 1993. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92: 2533-2539.
78. Hansen, M. B., M. Svenson, M. Diamant, K. Abell, and K. Bendtzen. 1995. Interleukin-6 autoantibodies: possible biological and clinical significance. Leukemia 9: 1113-1115.
79. Hansen, M. B., M. Svenson, M. Diamant, C. Ross, and K. Bendtzen. 1995. Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. Blood 85: 1145.
80. Hansen, M. B., M. Svenson, K. Abell, K. Yasukawa, M. Diamant, and K. Bendtzen. 1995. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur. J. Immunol. 25: 348-354.
81. Galle, P., M. Svenson, K. Bendtzen, and M. B. Hansen. 2004. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur. J. Immunol. 34: 3267-3275.
82. Hansen, M. B., V. Andersen, K. Rohde, A. Florescu, C. Ross, M. Svenson, and K. Bendtzen. 1995. Cytokine autoantibodies in rheumatoid arthritis. Scand. J. Rheumatol. 24: 197-203.
83. Suzuki, H., H. Takemura, K. Yoshizaki, Y. Koishihara, Y. Ohsugi, A. Okano, Y. Akiyama, T. Tojo, T. Kishimoto, and H. Kashiwagi. 1994. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J. Immunol. 152: 935-942.
84. Takemura, H., H. Suzuki, K. Yoshizaki, A. Ogata, T. Yuhara, T. Akama, K. Yamane, and H. Kashiwagi. 1992. Anti-interleukin-6 autoantibodies in rheumatic diseases: increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum. 35: 940-943.
85. Homann, C., M. B. Hansen, N. Graudal, P. Hasselqvist, M. Svenson, K. Bendtzen, A. C. Thomsen, and P. Garred. 1996. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand. J. Immunol. 44: 623-629.
86. Ku, C. L., H. von Bernuth, C. Picard, S. Y. Zhang, H. H. Chang, K. Yang, M. Chrabieh, A. C. Issekutz, C. K. Cunningham, J. Gallin, et al. 2007. Selective predisposition to bacterial infections in IRAK-4 deficient children: IRAK-4 dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204: 2407-2422.